Pieris Pharmaceuticals Received Nasdaq Notice Stating For Last 10 Consecutive Business Says, Closing Bid Price Was At $1 Or Greater
Portfolio Pulse from Benzinga Newsdesk
Pieris Pharmaceuticals has received a notice from Nasdaq indicating that for the last 10 consecutive business days, its closing bid price was at $1 or greater. This suggests that the company is currently in compliance with Nasdaq's minimum bid price requirement.
May 09, 2024 | 12:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pieris Pharmaceuticals has met Nasdaq's minimum bid price requirement, indicating a positive trend in its stock performance.
Meeting Nasdaq's minimum bid price requirement is a positive indicator of the company's stock performance and can prevent potential delisting. This compliance suggests investor confidence and a potentially stable or improving stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100